Sunny Pharmtech Inc. (TPEX:6676)

Market Cap	1.30B -37.4%
Revenue (ttm)	233.36M -19.6%
Net Income	-325.13M
EPS	-2.14
Shares Out	138.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	361,265
Open	9.50
Previous Close	9.67
Day's Range	9.25 - 9.75
52-Week Range	9.25 - 19.10
Beta	0.30
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Sunny Pharmtech

Sunny Pharmtech Inc. engages in the research, development, and sale of new and generic drug formulations and raw materials in Taiwan, the United States, and internationally. It offers lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; and aminocaproic acid ta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 160
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6676

Financial Performance

In 2025, Sunny Pharmtech's revenue was 253.01 million, a decrease of -39.47% compared to the previous year's 418.01 million. Losses were -302.05 million, 93.6% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 30, 2026

Data Sources Report a data error